AstraZeneca Bags US$1.2bn from Vaccine Sales in First Half

Translator:

Editor:

Laila Afifa

  • Font:
  • Ukuran Font: - +
  • TEMPO.CO, Jakarta - Multinational pharmaceutical company AstraZeneca booked US$1.2 billion from Covid-19 vaccine sales during the first half of 2021. The company made the revenue from selling 319 million doses of vaccine worldwide.

    Sales in the European region accounted for US$572 million of said income, while US$455 million came from sales in developing nations.

    The UK company based in Cambridge produces the Covid-19 vaccine that is also used in Indonesia.

    On the 13th of this month, Indonesian Foreign Affairs Minister Retno Marsudi announced the arrival of 3.4 million doses of AstraZeneca vaccine. They were delivered via COVAX (Covid-19 Vaccines Global Access), a multilateral initiative involving the World Health Organization (WHO).

    On July 16, the Health Ministry announced that Indonesia received 1 million more doses of vaccine from AstraZeneca. The ministry's secretary general, Oscar Primadi, said this was part of a bilateral agreement between AstraZeneca and the Government of Indonesia for the shipment of 50 million doses of vaccine.

    Read: UK to Donate 600,000 Covid-19 Vaccines to Indonesia This Week

    Fajar Pebrianto